

REMARKS

Claim 15 has been amended based on, e.g., the disclosure at page 10, line 3 in the specification. Claims 16 and 17 have been canceled. Claim 18 has been amended to recite Markush language and so that it is not broader than claim 15, the claim upon which it depends. Claim 19 has been amended so that it is not broader than claim 15, the claim upon which it depends. Claim 20 has been canceled. Claim 21 has been amended so that it is not broader than claim 15, the claim upon which it depends. Claims 22-25 have been canceled. Claim 26 has been amended for purposes of further clarification without narrowing its scope. Claim 27 has been added to recite a specific compound recited in claim 15 (see also, e.g., the disclosure of that compound in Lotion 1 in Example 1 on page 12 in the specification). Claim 28 has been added to recite a specific compound recited in claim 15 (see also, e.g., the disclosure of that compound in Lotion 1 in Example 2 on page 12 in the specification). Claims 29-33 have been added corresponding to claim 26 except for depending on claims 18, 19, 21, 27 and 28, respectively. Claims 34-39 have been added based on, e.g., the disclosure at page 10, line 3 in the specification and dependent on claims 15, 18, 19, 21, 27 and 28, respectively.

Entry of the above amendment is respectfully requested.

Applicants respectfully submit that the amended claims are allowable basically for the reasons of record. However, Applicants wish to note the following typographical errors in the record. In the table on the top of page 7 of the Amendment filed March 19, 2010, "d- α -tocopherol dimethylglycine ester hydrochloride" should have been "d,l- α -tocopherol dimethylglycine ester hydrochloride". Also, the Rule 132 Declaration filed in unexecuted form

SUPPLEMENTAL AMENDMENT
U.S. Application No.: 10/506,335

Attorney Docket No.: Q68931

on March 19, 2010 and in executed form on March 25, 2010 contained typographical errors in which "d,l- γ -tocopherol dimethylglycine ester hydrochloride" should have been "d- γ -tocopherol dimethylglycine ester hydrochloride". Accordingly, Applicants submit herewith a corrected executed Rule 132 Declaration.

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Bruce E. Kramer
Registration No. 33,725

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: May 17, 2010